Matribhumi Samachar English
Encinitas, California–(Newsfile Corp. – May 9, 2025) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced first quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key first quarter and 2025 year-to-date corporate highlights include: Received approval …
Read More »Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Ecinitas, California–(Newsfile Corp. – April 4, 2025) – Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company’s online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M. Strem, Ph.D., will provide an update on the …
Read More »Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
Encinitas, California–(Newsfile Corp. – March 25, 2025) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key fourth quarter and 2025 year-to-date corporate highlights include: Received approval to …
Read More »Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
Encinitas, California–(Newsfile Corp. – March 12, 2025) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt …
Read More »Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Encinitas, California–(Newsfile Corp. – February 11, 2025) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients with retinal macular edema, a condition where build-up of fluid behind part of the …
Read More »